Simple Summary Chimeric antigen receptor (CAR) T cell therapy has heralded a new era in
cancer treatment, in particular for hematological malignancies. Despite the current progress …

Regulatory T cells (Tregs) control immune homeostasis and prevent exacerbated immune
responses, and can be used as cell therapy to dampen a variety of autoimmune or …

The use of chimeric antigen receptor (CAR)-engineered regulatory T cells (Tregs) has
emerged as a promising strategy to promote immune tolerance. However, in conventional T …

Regulatory T cell (Treg) therapy is a promising strategy to treat inflammatory bowel disease
(IBD). Data from animal models has shown that Tregs specific for intestinal antigens are …

Autoimmune diseases (ADs) are among the most significant health complications, with their
incidence rising in recent years. Type 1 diabetes (T1D), an AD, targets the insulin-producing …

The manufacture of efficacious CAR T cells represents a major challenge in cellular therapy.
An important aspect of their quality concerns energy production and consumption, known as …

Recent clinical experience has demonstrated that adoptive regulatory T (Treg) cell therapy is
a safe and feasible strategy to suppress immunopathology via induction of host tolerance to …

Chimeric antigen receptor (CAR) T cells hold enormous potential. However, a substantial
proportion of patients receiving CAR T cells will not reach long-term full remission. One of …

Abstract CD4+FOXP3+ regulatory T cells (Tregs) control inflammation and enforce self-
tolerance to maintain immune homeostasis. Adoptive Treg cell therapy holds promise for a …